about
Targeted proteolysis of plectin isoform 1a accounts for hemidesmosome dysfunction in mice mimicking the dominant skin blistering disease EBS-OgnaAnticancer activity of methyl-substituted oxaliplatin analogs.Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones{(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo.Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).Resistance against novel anticancer metal compounds: differences and similarities.The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivoAnticancer activity of metal complexes: involvement of redox processes.Calpain-mediated integrin deregulation as a novel mode of action for the anticancer gallium compound KP46.Triapine and a more potent dimethyl derivative induce endoplasmic reticulum stress in cancer cells.Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity.Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes.The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells.Cisplatin and siRNA interference with structure and function of Wnt-5a mRNA: design and in vitro evaluation of targeting AU-rich elements in the 3' UTR.Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.Generation and characterisation of two D2A1 mammary cancer sublines to model spontaneous and experimental metastasis in a syngeneic BALB/c host.Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics
P50
Q27335461-491A1DB1-22A2-4E4E-A1F5-4C6EB1BB7477Q30515979-777DA8B4-A023-4E5E-BE9C-B0FDE5065C92Q35928856-F93A1D8C-2AF1-4995-99CD-FCF322DCF9ACQ36031384-B9F939CC-1EA5-4CDA-8AF4-369EC3DCF630Q36041069-63249208-A41A-4AF7-B8F4-6A028D09412CQ37131425-FFA3A011-1227-416C-9E5E-3297CF6328F6Q37253610-16893EBC-C2BC-47BF-854F-499E147D1B14Q37833099-9221416B-ABC0-4433-91CE-D5B99A444A50Q38969626-B7FC1838-A9BD-4C76-8260-EB5E1DECFD9BQ39038366-A143BF09-F6F3-415E-B571-F3ABF91E1B82Q39179140-85C2A286-1B47-449B-9199-EFD69B0F9511Q39625764-7FD55E11-8365-47F0-B293-4C5FBA6DB674Q39865512-2C1F773E-C1B6-4208-860A-30910D55CA07Q40040349-0A87DF02-A398-410B-9571-A1DE7E2CB44AQ42040747-E50AB67A-4C91-4538-B2DC-1E849E82BBECQ42712120-7A80CD43-C4A6-4B88-B11F-BA8DDFD007C7Q46417081-F796B659-32DF-402B-816D-18EB4B930A54Q47281042-886623DC-2F86-489C-849A-C6B4154BBADBQ64891091-B2858716-286C-41C8-9EA7-2AF0AAFFA53DQ93191053-AFC0B9B7-27A3-414A-8DD9-41FA2E4CE9E8
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ute Jungwirth
@ast
Ute Jungwirth
@en
Ute Jungwirth
@es
Ute Jungwirth
@nl
Ute Jungwirth
@sl
type
label
Ute Jungwirth
@ast
Ute Jungwirth
@en
Ute Jungwirth
@es
Ute Jungwirth
@nl
Ute Jungwirth
@sl
prefLabel
Ute Jungwirth
@ast
Ute Jungwirth
@en
Ute Jungwirth
@es
Ute Jungwirth
@nl
Ute Jungwirth
@sl
P106
P21
P31
P496
0000-0002-4673-3096